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Abstract: High rate of glycolysis is a metabolic hallmark of cancer. While anaerobic glycolysis promotes energy production under hy-
poxia, aerobic glycolysis, the Warburg effect, offers a proliferative advantage through redirecting carbohydrate fluxes from energy pro-
duction to biosynthetic pathways. To fulfill tumor cell needs, the glycolytic switch is associated with elevated glucose uptake and lactic 
acid release. Altered glucose metabolism is the basis of positron emission tomography using the glucose analogue tracer [18F]-
fluorodeoxyglucose, a widely used clinical application for tumor diagnosis and monitoring. On the other hand, high levels of lactate have 
been associated with poor clinical outcome in several types of human cancers. Although lactic acid was initially considered merely as an 
indicator of the glycolytic flux, many evidences originally from the study of normal tissue physiology and more recently transposed to 
the tumor situation indicate that lactic acid, i.e. the lactate anion and protons, directly contributes to tumor growth and progression. Here, 
we briefly review the current knowledge pertaining to lactic acidosis and metastasis, lactate shuttles, the influence of lactate on redox 
homeostasis, lactate signaling and lactate-induced angiogenesis in the cancer context. The monocarboxylate transporters MCT1 and 
MCT4 have now been confirmed as prominent facilitators of lactate exchanges between cancer cells with different metabolic behaviors 
and between cancer and stromal cells. We therefore address the function and regulation of MCTs, highlighting MCT1 as a novel antican-
cer target. MCT1 inhibition allows to simultaneously disrupt metabolic cooperativity and angiogenesis in cancer with a same agent, open-
ing a new path for novel anticancer therapies. 
Keywords: Tumor metabolism, hypoxia, Warburg effect, lactate, lactic acidosis, monocarboxylate transporters, hypoxia-inducible factor-1, 
nuclear factor-?B. 
INTRODUCTION 
 Cancers exhibit extensive heterogeneity in almost all pheno-
typic features, such as cellular morphology, gene expression, me-
tabolism, as well as angiogenic, proliferative, and metastatic poten-
tials. This heterogeneity is mainly attributed to multiple mutations 
in oncogenes and tumor suppressor genes. Some of them may have 
a genetic predisposition to microenvironmental stresses such as 
hypoxia, depletion of glucose and other nutrients, and acidosis.  
 Under normoxic conditions, quiescent cells in normal tissues 
generally depend on energetically efficient aerobic metabolic path-
ways to generate ATP. Glucose enters into the cells through glucose 
transporters (primarily GLUT1 to GLUT4), is sequestered intracel-
lularly in the form of glucose-6-phosphate (G6P) after phosphoryla-
tion by hexokinases (HKs), and undergoes glycolysis to generate 
pyruvate. If glucose is fully metabolized through glycolysis, two 
molecules of pyruvate are produced per molecule of glucose con-
sumed. Then, the fate of pyruvate depends on the oxygen condition 
prevailing in the tissue. Under aerobic conditions, pyruvate enters 
into mitochondria where it is converted to acetyl-CoA in the pyru-
vate dehydrogenase (PDH) reaction, and acetyl-CoA enters into the 
tricarboxylic acid (TCA) cycle to be metabolized to CO2, H2O and 
energy metabolites. Glycolysis coupled to oxidative phosphoryla-
tion (OXPHOS, Table 1 is a box defining specific terminology) 
yields up to 38 molecules of ATP per molecule of glucose. In an-
aerobic conditions, the limited availability of O2 to accept electrons 
from the electron transport chain slows down the OXPHOS flux. A 
significant proportion of pyruvate is reduced into lactate by lactate 
dehydrogenase-5 (LDH-5), a reaction serving to perpetuate anaero-
bic glycolysis by oxidizing NADH into NAD
+
 to aliment the glyc-
eraldhehyde-3-phosphate dehydrogenase (GAPDH) reaction 
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Table 1. Terminology Box. 
Term Definition 
Anaplerosis Processes that replenish the TCA cycle with energy-
containing intermediates to produce ATP in the mito-
chondrion. 
Cataplerosis Processes that deplete the TCA cycle through redirect-
ing energy-containing intermediates from ATP produc-
tion in the mitochondrion towards biosynthetic path-
ways.  
Oxidative 
phosphoryla-
tion 
An  oxygen-dependent process that occurs in mito-
chondria where it couples the oxidation of macromole-
cules and electron transport with the production of 
ATP. 
Pasteur 
effect 
Negative feedback exerted by energy metabolites on 
key glycolytic enzymes. 
Warburg 
effect 
Uncoupling between glycolysis and oxidative phos-
phorylation commonly observed in proliferating cells 
including tumor cells.  
 
Fig. (1). An inverse correlation between intracellular pyruvate lev-
els and the activity of histone deacetylases in colon cancer cells 
further suggested that the LDH-5 reaction could prevent pyruvate-
induced apoptosis [1, 2]. However, although pyruvate in these stud-
ies induced colon cancer cell death upon ectopic re-expression of 
the pyruvate-sodium symporter SLC5A8 [1, 2], SLC5A8 is usually 
silenced in cancer cells [3] and we have found that exogenous py-
ruvate (delivered at a 10 mM concentration in its methyl-esterified 
form to human cervix cancer cells) rather supports tumor cell sur-
vival [4]. Generation of lactate under hypoxia is further facilitated 
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by the increased activity of pyruvate dehydrogenase kinase 1 
(PDK1) that blocks PDH activity [5, 6], and by the conversion of 
malate, a cataplerotic product of anaerobic mitochondrial activity, 
into pyruvate by the malic enzyme [7]. Lactate serves as a counter-
ion for the export of protons, a process meant to avoid intracellular 
acidification and facilitated by the lactate-proton symporter mono-
carboxylate transporter 4 (MCT4) [8] Fig. (1). Although glycolysis 
uncoupled from OXPHOS only yields 2 molecules of ATP per 
molecule of glucose, several molecular pathways including hy-
poxia-inducible transcription factor-1 (HIF-1), c-Myc, AMP-
activated protein kinase (AMPK) and molecular target of rapamy-
cin (mTOR), cooperate to accelerate the glycolytic flux, as recently 
reviewed in reference [9]. Consequently, anaerobic glycolysis of-
fers the possibility to match cell energy production with demand 
under hypoxia, at the expense of high glucose consumption and 
abundant lactic acid release. Lactate levels in tumors can indeed 
reach up to 40 mM, with an average level of 10 mM [10]. 
 The glycolytic switch represents more than a mere adaptation to 
hypoxia. Indeed, some tumor cells especially in advanced cancers 
may perform aerobic glycolysis (i.e., high rate of glycolysis uncou-
pled from OXPHOS even in the presence of O2), a metabolic phe-
notype known as the Warburg effect [11]. Constitutive upregulation 
of glycolysis under normoxic conditions allows carbohydrates to be 
redirected to biosynthetic pathways instead of getting cleaved to 
lactate, thus promoting tumor cell proliferation and tumor growth. 
These pathways include the pentose phosphate pathway (PPP) for 
DNA synthesis and NADPH production, alanine biosynthesis from 
pyruvate, and cataplerosis during which organic acids produced in 
the TCA cycle are exported from mitochondria to promote lipid 
synthesis and amino-acid synthesis and exchanges. 
 High rate of glucose uptake associated with increased glycolytic 
fluxes has been exploited clinically for the detection of tumors us-
ing positron emission tomography (PET) with the radiolabeled 
glucose analogue tracer [
18
F]-fluorodeoxyglucose (FDG) [12]. 
FDG-PET has high sensitivity for metastases, making it a prevail-
ing clinical tool for diagnosis (see references [13, 14] for compre-
hensive reviews). Elevated rates of FDG uptake have further shown 
a strong negative correlation with patient outcome in many cancers 
[13, 14]. Interestingly, although no clinical diagnostic application 
has been developed to date, studies concerning lactate accumulation 
in human tumors have shown that tumors with metastatic spread 
such as cervical tumors, head and neck cancers and rectal adenocar-
cinomas, exhibit a wider range and higher levels of lactate as com-
pared to non-metastatic tumors [15-19]. Elevated levels of lactate 
also showed a correlation with poor patient prognosis and overall 
survival in cervical cancer [17], head and neck cancer [18], high 
grade gliomas [20-22] and non small cell lung cancer [23]. This 
makes lactate a suitable candidate as a diagnostic and prognostic 
indicator for a wide variety of tumors. While most of these studies 
considered lactic acid merely as a byproduct of fermentative glyco-
lysis and consequently lactate measurements as a reflection of the 
glycolytic activity of tumors, lactic acid itself could be an important 
tumor growth-promoting factor. This review briefly summarizes the 
current understanding of the multiple biological activities of lactic 
acid in cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Model of lactate shuttles in cancer. Solid tumors typically comprise oxygenated tumor cells close to blood vessels and hypoxic cells at distance 
from blood vessels. Hypoxic cells produce energy from glucose using glycolysis uncoupled from oxidative phosphorylation of the tricarboxylic acid (TCA) 
cycle, which requires high-rate glucose import by glucose transporters (GLUT) to produce 2 ATP per molecule of glucose. Pyruvate, produced either from 
glycolysis or generated by the malic enzyme (ME) from cataplerotic malate, is reduced to lactate by lactate dehydrogenase-5 (LDH-5). NADH is oxidized to 
NAD+, which is as a substrate of glyceraldehyde-3-P (P = phosphate) dehydrogenase (GAPDH) and therefore maintains glycolysis at high rate. Lactate is 
exported together with a H+ by monocarboxylate transporters (MCT), primarily MCT4. Once exported from glycolytic tumor cells or, as recently described 
[32], from stromal cells, lactic acid readily dissociates to lactate and H+ (lactic acidosis). Oxidative tumor cells have a preference for lactate compared to glu-
cose to fuel their oxidative metabolism [4, 125]. Lactate together with a H+ is taken up by MCT1, oxidized to pyruvate by LDH-1, and pyruvate is incorporated 
into the TCA cycle to yield up to 18 ATP per molecule of lactate. CO2 is produced and exported to the extracellular space where it generates bicarbonate and 
additional H+ (carbonic acidosis). According to the model, tumors are metabolic symbionts in which lactate as a preferential oxidative fuel increases glucose 
bioavailability for glycolytic activities. Disrupting the symbiosis therapeutically is achievable with MCT inhibitors, especially drugs targeting MCT1 in cells 
close to blood vessels [30, 166]. 
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LACTIC ACID: FROM WASTE BYPRODUCT TO TUMOR-
GROWTH PROMOTING AGENT 
 In biological fluids, lactic acid (pKa 3.86) is almost 99 % disso-
ciated into lactate anions and protons [24]. For much of the 20th 
century, lactic acid was largely considered as a dead-end waste 
product of glycolysis, a major cause of muscle fatigue, and a key 
factor in acidosis-induced tissue damage. In 1929, Carl and 
Gertrude ‘Gerty’ Cori [25] demonstrated that the liver takes up 
circulating lactate from the blood to undergo hepatic gluconeogene-
sis, a phenomenon nowadays known as the Cori Cycle. Lactate 
uptake and metabolism were later studied in the muscle, leading to 
the emergence of the concept of lactate shuttles initially between 
muscle cells [26], then between different intracellular compart-
ments [27], and more recently between different cell populations 
within a same organ as exemplified by the astrocyte-neuron lactate 
shuttle in the brain [28]. These seminal advances in our understand-
ing of lactate activities in normal tissues have only recently been 
translated into new knowledge in the tumor context. Increasing 
evidence indicates that lactate in tumors is a fuel for the oxidative 
metabolism of oxygenated tumor cells [4, 29-33], a signaling agent 
in tumor and endothelial cells [34-36], and an important contributor 
to wound repair and angiogenesis [37-39]. Here, we review these 
biological actions of lactate in cancer first by describing the neces-
sary lactate transporters mediating lactate exchanges. We then focus 
on lactate shuttling, starting with insights from normal tissue physi-
ology to the hypothesis of a tumor metabolic symbiosis in cancer, 
to conclude with descriptions of extracellular (lactic acidosis at the 
bedside of metastasis) and intracellular influences on redox homeo-
stasis, lactate signaling and tumor angiogenesis. 
LACTATE TRANSPORTERS AND THEIR REGULATION 
IN CANCER 
 Lactate is an anion and therefore requires transporters to effi-
ciently cross cell membranes. This function is predominantly ex-
erted by transporters of the MCT family. MCTs are proton-coupled 
12-span transmembrane proteins with both N-terminal and C-
terminal tails located in the cytosolic domain. Of the 14 identified 
MCTs encoded by the SLC16A gene family, only 6 are functionally 
characterized to date [40]. Of these, MCT1 to MCT4 are able to 
carry out the proton-coupled transport of lactate across cell mem-
branes. They behave as passive transporters driven by the gradient 
of protons across cell membranes and are not selective for lactate. 
With the highest affinities for lactate, MCT2 (Km lactate = 0.5 mM) 
and MCT3 (Km lactate = 5 mM) are specialized in the import of lac-
tate but only in very specific tissues such as the liver (Cori cycle), 
the kidney and the brain for MCT2, and the retina for MCT3 [41-
43]. MCT1 is ubiquitously expressed and has an intermediate affin-
ity for lactate (Km lactate = 3.5-10 mM). It may function bidirection-
ally depending on the cellular and environmental context: for ex-
ample outwardly in erythrocytes [44], proliferating lymphocytes 
[45] and some tumor cells [46]; and inwardly in slow-twitching 
muscle fibers [47], neurons [28], endothelial cells [36], and oxida-
tive tumor cells [4, 33]. With the lowest affinity for lactate and a 
high turnover rate, MCT4 (Km lactate = 22 mM) is adapted for the 
export of lactic acid from glycolytic cells [8]. The other transporters 
of the MCT family have been identified to transport other endoge-
nous and/or exogenous molecules, for instance diuretics (MCT6), 
thyroid hormones (MCT8) and aromatic amino acids (MCT10) [48, 
49]. 
 The transport of lactate is of critical importance for tumors with 
elevated glycolysis, not only to prevent cellular acidification 
through exporting lactic acid, but also to sustain growth through 
importing lactate, as detailed below. In the vast majority of tumors 
analyzed to date, MCT1 and MCT4 play a predominant role, but 
exceptions exist. For example, MCT1 and MCT2 are apparently the 
primary isoforms expressed in human glioblastoma multiforme and 
glioma-derived cell lines; targeting these MCTs with specific siR-
NAs in U-87 cells significantly reduced cell viability [50]. The 
membrane expression and function of MCT1 and MCT4 are de-
pendent on their association with the mature glycosylated form of 
the chaperone protein basigin/CD147, also known as extracellular 
matrix metalloproteinase inducer (EMMPRIN) [48, 51, 52]. Con-
versely, CD147 is also affected by MCT expression: in the breast 
cancer cell line MDA-MB-231, MCT4 regulates the maturation and 
trafficking of CD147 to the plasma membrane [53], whereas in 
Caco-2 cells, silencing of MCT1 leads to accumulation of the im-
mature and core-glycosylated form of CD147 [52]. Additional 
MCT chaperones may exist. CD44 was indeed shown to co-
immunoprecipitate with and to regulate the intracellular trafficking 
of MCT1 and MCT4 in breast cancer cells [54]. Another report 
suggests the existence of an additional chaperone protein different 
from CD147 and CD44 in human tumor biopsies where a mismatch 
was observed between the plasma membrane expression of MCTs, 
CD44 and CD147 [46].  
 There have been several reports discussing changes in MCT 
expression in different types of cancers. In xenografts of the human 
cervix carcinoma cell line SiHa and human colon cancer cell line 
WiDr, we have, for example, reported a preferential expression of 
MCT1 in normoxic cells with oxidative potential [4], and others in 
other models have reported that MCT4 expression is predominant 
in glycolytic/hypoxic cells [55]. MCT localization and function 
could therefore be matched. Accordingly, MCT4 has been identi-
fied as a HIF-1-target gene product that facilitates the release of 
lactate from glycolytic cells [8, 56], and MCT1 could primarily 
mediate lactate uptake by oxygenated cells in tumors [4, 33]. How-
ever, little is known about the regulation of its expression. Although 
by using the hypoxia marker EF5 and immunohistology we have 
confirmed the absence of MCT1 in hypoxic areas of primary human 
lung cancer biopsies [4], hypoxia may not exert its influence inde-
pendently of other factors: in vitro, hypoxia did not significantly 
decrease MCT1 mRNA and protein expression in HeLa cells [56]. 
In support of additional microenvironmental controls, in vivo mus-
cle studies showed increased MCT1 protein expression in response 
to exercise [57], which was better characterized in vitro by showing 
that lactate promotes both MCT1 and CD147 transcription and 
protein expression in rat and human muscles [58]. To our knowl-
edge, a similar regulation has not been reported in cancer cells. 
Interestingly, hypermethylation of a CpG island in the 5’ upstream 
region of the SLC16A1 gene encoding MCT1 has been demon-
strated in the notably Warburg phenotype MDA-MB-231 cell line, 
and proposed to account for gene silencing [59]. However, this 
study was not supported by measurements of MCT1 protein expres-
sion.  
 Cancer cells like those of esophageal squamous cell carcinomas 
and endometrial carcinomas have been shown to have an elevated 
expression of CD147, which the corresponding normal tissues do 
not express [60-62]. Through homophilic interactions, elevated 
CD147 in tumor cells stimulates the production of matrix metallo-
proteinases (MMPs) 1, 2, 3, 9, 11, 14 and 15 by neighboring tumor 
cells, stromal fibroblast and endothelial cells [63], leading to a re-
modeling of the extracellular matrix promoting tumor growth and 
tumor cell mobility [64-66]. Many of these MMPs are notoriously 
associated with malignant cancers [67]. CD147 was also reported to 
stimulate vascular endothelial growth factor (VEGF) production 
through the PI(3)K/Akt pathway [68], potentially contributing to 
tumor aggressiveness by stimulating angiogenesis. To what extent 
its interactions with MCTs participate to the tumor growth-
promoting activities of CD147 is still largely unknown.  
 Sodium-coupled MCTs (SMCTs) belonging to the SLC5A fam-
ily transport substrates similar to those carried by SLC16A MCT 
family members. SMCT1, which has a very high affinity for lactate 
(Km lactate = 160-240 ?M), regulates the uptake of short-chain fatty 
acids in the colon [69] and the tubular reabsorption of lactate and 
pyruvate in the kidney [70]. In colon cancer, rather than primarily 
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ensuring lactate exchanges, it behaves as a tumor suppressor by 
mediating the uptake of pyruvate and butyrate, two pro-apoptotic 
molecules acting as potent inhibitors of histone deacetylases (see 
reference [71] for an extensive review). Consequently, SMCT1 is 
silenced in many types of cancers, including colon, thyroid, stom-
ach, brain, breast, pancreas, and kidney cancers [3]. 
LACTATE SHUTTLES IN CANCER: FROM NORMAL TIS-
SUE PHYSIOLOGY TO THE HYPOTHESIS OF A META-
BOLIC SYMBIOSIS IN TUMORS 
 Muscle cells and myocytes use glucose, fatty acids and ketone 
bodies as energy sources to generate ATP. During intense exercise, 
fast-twitching glycolytic muscle fibers (white muscle) become hy-
poxic and produce lactic acid, which is then released to the ex-
tracellular compartment. Once exported, extracellular lactate may 
be taken up by slow-twitching muscle fibers (red muscle) where it 
is utilized as a respiratory fuel, or shuttled into the blood stream for 
further clearance. Lactate export and uptake is a MCT-dependent 
process reviewed in reference [72]. Briefly, muscles express MCT1 
and MCT4 with isoform-specific pattern: tissues like heart and 
oxidative red muscle show higher expression of MCT1, whereas 
MCT4 expression is seen largely in glycolytic white muscles [47]. 
Lactate shuttles between glycolytic muscle fibers (where it is pro-
duced) and oxidative muscle fibers where, after oxidation to pyru-
vate by LDH-1, it fuels the TCA cycle. Interestingly, training in-
creases MCT1 expression and the anaerobic threshold point at 
which lactate starts to accumulate in the blood [73]. Conversely, 
human patients deficient for MCT1 expression experience reversi-
ble muscle cramps upon intensive exercise, a condition known as 
cryptic exercise intolerance [74]. 
 A similar lactate shuttle is proposed between astrocytes and 
neurons in the brain. Recent studies have shown that the brain tis-
sue is a fervent consumer of lactate from blood and there is evi-
dence that lactate is a preferred metabolic substrate for neurons 
even in presence of glucose [75, 76]. Nuclear magnetic resonance 
(NMR) studies in the brain have indeed shown that on elevating 
plasma lactate levels, the uptake of glucose decreases [77]. Astro-
cytes express both MCT1 and MCT4 and perform aerobic glycoly-
sis, exporting a substantial amount of lactate into the extracellular 
space. Lactate is then taken up by the neighboring neurons through 
the high affinity lactate transporter MCT2 expressed on the cell 
surface [43, 48]. NMR studies have shown that following [13C]-
lactate administration, the labeled isotope was traced to TCA cycle 
intermediates and amino acids [78].  
 Both muscle and brain point towards a two compartment shut-
tle, wherein in one location lactate is produced glycolytically and at 
the other location it is utilized oxidatively. Similarly, the vast ma-
jority of solid tumors also contains populations of glycolytic tumor 
cells (being aerobic or not) and oxidative tumor cells. On this basis 
and because tumors are known usurpers of physiological functions, 
we [4] have studied lactate shuttling in cancer. We found that lac-
tate is an important metabolic fuel for oxygenated tumor cells Fig. 
(1). In presence of glucose and lactate, these cells switch from glu-
cose to lactate uptake and thus import consistently less glucose as 
compared to the situation when no lactate is supplied in the media. 
When glucose is removed, oxidative tumor cells import large 
amounts of lactate that is used to fuel the TCA cycle for ATP pro-
duction. In this study, we therefore proposed that the existence of 
the hypoxic tumor cell compartment relies on a metabolic symbio-
sis by which glycolytic/hypoxic and oxidative/oxygenated tumor 
cells mutually regulate their access to energy metabolites. The sym-
biosis involves lactate recycling: oxidative tumor cells prefer to use 
lactate in the presence of glucose as an oxidative fuel, allowing 
glucose to diffuse farther from blood vessels where it is taken up by 
glycolytic tumor cells, in turn producing lactate in large quantities 
Fig. (1). In tumor cells under aerobic conditions, we proposed that 
lactate oxidation is more efficient than glucose as the latter claims 
initial energy input for phosphorylative reactions and the homeosta-
sis of glycolytic enzymes, whereas each molecule of lactate pro-
duces up to 18 ATP. Oxidation of lactate into pyruvate by LDH-1, a 
necessary step for anaplerosis with lactate, further involves the 
continuous production of reduced NADH that could buffer oxida-
tive stress. Several observations support the symbiont hypothesis: 
(i) inhibition of MCT1, which we found to be the prominent path 
for lactate uptake by oxidative tumor cells, induces hy-
poxic/glycolytic tumor cell death in vivo as a consequence of a 
metabolic switch from lactate-fueled respiration to glycolysis in the 
oxidative tumor cell compartment [4], (ii) MCT1 is expressed in an 
array of primary human tumors and preferentially in normoxic tu-
mor cells in biopsies of lung cancer [4], and (iii) ex vivo measure-
ments made at early time points during chronic MCT1 inhibition 
with the experimental drug ?-cyano-4-hydroxycinnamate (CHC) 
showed significant inhibition of the Pasteur effect in FaDu and 
SiHa tumor xenografts [79]. The latter study, however, failed to 
evidence a reduction in average glucose levels and hypoxia in vi-
able tumor areas 4 hours (FaDu) and 4 days (SiHa) after initiating 
CHC delivery, whereas in other models we evidenced radiosensiti-
zation after 3 days (LLc) and reduced hypoxia after 18 days of 
treatment (WiDr) [4]. These disparities may well be explained by 
our incomplete understanding of the pharmacology of CHC (includ-
ing biodistribution with respect to different tumor models and/or 
different treatment times), which certainly warrants further investi-
gation. Other MCT1 inhibitors with increased inhibitory activities 
have been identified [80, 81]. The high clinical potential of target-
ing tumor symbiosis with MCT1 inhibitors is currently being inves-
tigated with AZD3965, an orally administered compound now en-
tering Phase I/II clinical trials for advanced solid tumors 
(http://science.cancerresearchuk.org/). An alternative could be to 
target lactate export through MCT4 [53], but the strategy is con-
fronted with the difficulty of reaching the target in vivo (a large 
proportion of hypoxic/glycolytic tumor cells are located at distance 
from drug-supplying blood vessels), and no specific small molecule 
inhibitor nor blocking antibody selective for MCT4 has been identi-
fied so far. Interestingly, metabolic cooperativity in tumors has 
recently been shown to involve stromal cells: cancer-associated 
fibroblasts have been reported to be glycolytic and to fuel the oxi-
dative metabolism of cancer cell [31, 32]. Co-culture experiments 
supported with analyzes of human breast cancer samples also 
showed increased MCT4 expression in stromal cells, whereas 
MCT1 expression was increased in tumor cells [33], thus revealing 
an additional rationale for anticancer MCT1 inhibition. 
LACTIC ACID IN TUMOR INVASION AND METASTASIS 
 Glycolysis is nominally a faster succession of reactions than 
ATP production through OXPHOS [82]. Compared to normal 
paced OXPHOS, high rate of glycolysis coupled to biosynthetic 
pathways yields an elevated production of lactic acid, which must 
be exported to avoid intracellular acidification and death. A direct 
mechanism is provided by MCTs which, as passive lactate-proton 
symporters, couple the export of each molecule of lactate with a 
proton. With low affinity for lactate but hypoxia-induced expres-
sion and a high turnover rate [55, 56], MCT4 is particularly well 
adapted to ensure this function [8]. It does not exclude the contribu-
tion of other MCTs such as MCT1. It is particularly striking to real-
ize that the lactate concentration detected in human tumors such as 
cervix cancer may range from 4 mM up to 40 mM (median 14 mM) 
[18], whereas the physiological concentration of lactate in normal 
tissues at rest is set between 1.8 mM and 2 mM [16, 24]. It repre-
sents at least an equivalently high release of protons, not taking into 
account lactic acid recycling by oxidative tumor cells Fig. (1) and 
the clearance of lactate by circulation. Besides MCTs, the equip-
ment of tumor cells ensuring proton export includes carbonic anhy-
drases, membrane-bound vacuolar ATPase (V-ATPase), and the 
sodium proton exchanger NHE1 (recently reviewed in reference 
[9]). These activities collectively create a transmembrane gradient 
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of protons opposite to that in normal cells: in cancer cells, the intra-
cellular pH (pHi) is either neutral or even slightly alkaline (pH ? 
7.4), and extracellular pH (pHe) is acidic (pH = ~6.7 - 7.1) [83, 84]. 
Alkaline pHi provides a supplemental glycolytic advantage to tumor 
cells: the activity of LDH-5 is maximal at pH 7.5 [85], and the ac-
tivity of phosphofructokinase-1 (PFK1) increases with the pH due 
to the repression of allosteric repressors [86]. 
 There are two main forms of acid in tumors: carbonic acid (car-
bonic acidosis) and lactic acid (lactic acidosis). Glucose and lactate 
respiration, glutaminolysis (fueling the TCA cycle), cataplerosis 
(which necessitates TCA cycle activities but no O2 consumption), 
malate decarboxylation (malic enzyme reaction), and overactive 
PPP (producing 1 CO2 per molecule of G6P), as well as titration of 
bicarbonate with metabolically produced acids, are important 
sources of CO2 [9, 87, 88]. It is important to stress out that glycoly-
sis when yielding 2 molecules of lactate from 1 molecule of glucose 
does not contribute directly to the production of protons required 
for lactate exportation. On one hand, the various sources of CO2 
listed above may (OXPHOS, glutaminolysis, oxidative arm of the 
PPP) or may not (cataplerosis, malate decarboxylation) be coupled 
with oxygen consumption, and CO2 may generate H
+
 and HCO3
-
 
intracellularly following hydration by carbonic anhydrases (CAs) 
[89]. On the other hand, ATP hydrolysis and the catabolism of ni-
trogen may be other sources of acidity. The hypothesis that lactic 
acid is a major cause of tumor acidification is based on a correlation 
between elevated lactic acid concentration and low pHe in tumors 
[90]. However, other studies have shown that tumors derived from 
glycolysis-deficient cells (lacking phosphoglucose isomerase activ-
ity or LDH) still produced a pHe of 6.7 (i.e., as low as with parental 
tumors) despite negligible lactic acid production in vitro [91, 92]. 
The authors concluded that lactic acid production is not the only 
and perhaps even not a major cause of tumor acidification. Support-
ing these conclusions, it was observed that both pCO2 and bicar-
bonate levels were higher in the interstitial fluids around glycolysis-
deficient tumors as compared to those in normal tissues [87]. Others 
reported a high pCO2 in rodent solid tumors (59 - 84 mm Hg versus 
50 - 66 mm Hg for venous blood) [93], further indicating that CO2 
rather than lactic acid could be the main contributor to tumor acidi-
fication. Once produced, CO2, being freely membrane permeable, 
exits the cell. Located at the cell membrane with an extracellular 
orientation, CAIX catalyses the hydration of CO2 into HCO3
-
 and 
H
+
, thereby contributing to extracellular acidification of the tumor 
microenvironment [94]. 
 Several studies have described the key contribution of tumor 
acidity to local invasion and metastasis, which has been the topic of 
recent reviews [95, 96]. Briefly, changes in the tumor microenvi-
ronment bestow clever proliferative advantages on the tumor cells 
for invading the adjacent normal tissue. Indeed, extracellular acidi-
fication leads to obliteration of normal tissues via caspase-mediated 
activation of p53-dependent apoptotic pathways [97, 98], whereas 
cancer cells are well equipped to export protons (reviewed in refer-
ence [9]) and/or lack p53 expression [98]. In addition, a low pHe 
promotes (i) angiogenesis through acid-induced expression of 
VEGF and IL-8 [99, 100], (ii) extracellular matrix degradation 
through activating proteolytic enzymes such as cathepsin B [101, 
102], and (iii) inhibition of immune functions [103]. One of the 
most characterized influences of acidosis to cancer progression is 
metastasis facilitation. Cancer cells on their metastatic route wave 
their way through the extracellular matrix (ECM), which requires 
ECM degradation and remodeling, a process facilitated by extracel-
lular acidification [96, 104]. It has been shown that low pHe pro-
vides a favorable microenvironment for the activation of proteases, 
including MMPs [105, 106], urokinase-type plasminogen activator 
[107], and cathepsins B [101, 102, 108], D [109], and L [110]. For 
example, maximal activity of human MMP-3 is seen within the 
optimum pH range of 5.75 to 6.25 [105]. Acidosis also contributes 
to MMP activation by promoting the proteolytic cascade that con-
verts pro-MMPs to active MMPs, as is the case for MMP-9 [106]. 
 Studies of lactic acidosis have largely neglected the contribu-
tion of the lactate anion to tumor invasion and metastasis, which 
has only recently gained some attention. Interestingly, Izumi et al. 
[111] showed that, in addition to MCT4 (creating extracellular 
acidification), MCT1 plays an important role in tumor cell invasion. 
MCT1 expression indeed correlated with in vivo invasiveness of 
human lung cancer cells and MCT1 inhibitors decreased both mi-
gration and invasiveness. Interestingly, in the same study [111], 
MCT1 deletion reduced tumor cell migration to a larger extend than 
CD147 silencing, suggesting a contribution of MCT1 not overlap-
ping the well-known pro-metastatic activities of CD147 [63-66]. 
Whether changes in intra- or extra- cellular lactate concentration 
drive tumor cell migration and invasion remains an open question. 
On one hand, Izumi et al. [111] using A110L lung tumor cells ex-
pressing both MCT1 and MCT4 failed to show a significant influ-
ence of exogenous sodium lactate (5 mM) on cell migration and 
invasion over a 22-h time course. In the same pH-buffered condi-
tions, there was no correlation between extracellular lactate levels 
and invasion activities. On the other hand, others [112] showed that 
sodium L-lactate (10 – 40 mM) but not D-lactate or changes in 
osmolarity or intracellular pH induced a time- and dose-dependent 
migration of human SQ20B squamous larynx carcinoma cells in 
Boyden chamber assays. Migration was random (as observed using 
videomicroscopy) and was also stimulated by pyruvate, suggesting 
that lactate oxidation into pyruvate could be involved in the migra-
tory phenotype of these tumor cells [112]. Further studies are 
needed to confirm and further identify the underlying mecha-
nism(s). In another set of experiments, lactate was shown to stimu-
late the production of hyaluronan (HA) and the expression of 
CD44, its main transmembrane receptor, by fibroblasts [113] and 
melanoma cells [114]. In fibroblasts, it is supported by the exis-
tence of a lactate-induced transcriptome, including genes encoding 
CD44 and hyaluronidases HYAL1 and HYAL2, but also c-fos, c-
jun, c-ets, and caveolin-1 [115]. HA-induced activation of CD44 at 
the tumor cell surface reduces cell adherence and promotes cell 
mobility, as reviewed in reference [116]. Still in line with a poten-
tial involvement of lactate in metastasis, it has been shown that 
lactate upregulates the expression of transforming growth factor ?2 
(TGF-?2) in glioblastoma cells [117]. TGF-?2 is a key regulator of 
invasion in high-grade gliomas, inducing a mesenchymal pro-
migratory phenotype and promoting ECM remodeling [118, 119]. 
Thus, lactate-induced TGF-?2 expression could play a role in brain 
metastasis. 
 Lactate and lactic acid are often confounded. While the contri-
bution of acidosis to tumor progression and metastasis is well 
documented, the role of the lactate anion is only starting to be char-
acterized. Based on existing data, one may envision a potential use 
of MCT inhibitors for the modulation of cancer metastasis, as pre-
viously suggested by others [111]. 
LACTATE AND INTRACELLULAR REDOX POTENTIAL 
 The mitochondrion is a main site of O2 consumption in the cell 
and any reduction in pO2 leads to the increased production of reac-
tive oxygen species (ROS). If hypoxia persists, the transcription 
factor HIF-1 along with c-Myc stimulates adaptive mechanisms to 
reduce ROS and to re-establish redox homeostasis. Indeed, when 
PDH is inhibited by the HIF-1-target gene product PDK1 under 
hypoxia, the glycolytic flux is pushed towards the LDH-5 reaction 
for NAD
+
 production, which prevents excessive ROS production 
[5, 6, 120]. HIF-1 activation is further promoted by ROS them-
selves [121].  
 Pyruvate represents a crucial metabolic regulatory point. It is 
the product of glycolysis, the product of malate decarboxylation, a 
main fuel for the TCA cycle, and it can be converted to lactate by 
LDHs in a reversible redox reaction Fig. (1). Due to different affini-
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ties for their substrates, LDH-5, a target gene product of c-Myc and 
HIF-1, preferentially couples the reduction of pyruvate into lactate 
with the oxidation of NADH into NAD
+
 [122], whereas LDH-1 
preferentially catalyzes the reverse reaction and is most generally 
silenced in glycolytic cancer cells [2, 123]. The LDH-5 reaction 
serves to replenish the NAD
+
 pool to make glycolysis self-
sufficient. As a product of pyruvate reduction in glycolytic cells and 
as a substrate for pyruvate generation in oxidative tumor cells, lac-
tate influences the NADH/NAD
+
 ratio and thereby the cell redox 
status Fig. (1). Lactate as a fuel further influences cell metabolism 
through competing with the GAPDH reaction for NAD
+
 (LDH-1 
being a more efficient user of NAD
+
) [4, 124], and potentially 
through allosterically inactivating the glycolytic enzymes HKs (as 
shown in skeletal muscle and liver) and phosphofructokinase (liver 
and kidney) [125]. Interestingly, transactivation mediated by HIF-1 
and HIF-2 can be modulated by NAD
+
 levels, providing a further 
link between the interconversion of lactate and pyruvate, cell me-
tabolism and tumor progression: the NAD
+
-dependent enzyme 
poly(ADPribose) polymerase 1 (PARP1) binds to HIF-1? and co-
activates HIF-1-dependent gene expression [126], and the NAD
+
-
dependent deacetylase sirtuin 1 (SIRT1) increases transcriptional 
activation by HIF-2 but not by HIF-1 [127]. 
LACTATE SIGNALING 
 Lactate is not only a metabolic intermediate; it may also act as a 
signaling molecule. Lactate (20 mM, 6-h) was indeed shown to 
activate the transcription of 673 genes in L6 myocytes, including 
genes involved in metabolism and mitochondrial activities, tran-
scription activation, signal transduction, transport, oxidative stress, 
apoptosis, cell growth, and calcium signaling (see the supplemental 
data of reference [58] for a complete list of genes). Only 3 genes 
were downregulated. Interestingly, among the regulated genes were 
Jun (a component of AP-1 transcription factor), Ras and CREB 
(effectors of the mitogen-activated protein kinase [MAPK] path-
way), suggesting a lactate-induced activation of ROS-sensitive 
pathways. Lactate indeed induced a small but significant increase in 
ROS production and stimulated the DNA binding of NF-?B and 
NRF-2, as shown using electrophoretic mobility shift assays [58]. 
AP-1 activation was not evidenced. Increased activity of NRF-2 
together with increased DNA binding of CREB suggests that lactate 
could be involved in mitochondrial biogenesis (as also documented 
with increased cyclooxygenase-IV expression in whole muscle 
homogenates), which is physiologically relevant for an increased 
clearance of lactate by oxidative muscle fibers [58].  
 In the context of cancer, lactate has been identified as a hy-
poxia-mimetic able to activate the transcription factor HIF-1 origi-
nally in normoxic glioma cells [34, 35]. The underlying pathway 
was shown to require lactate oxidation into pyruvate (LDH-1 reac-
tion) in order to support a functional competition between pyruvate 
and 2-oxoglutarate (a by-product of the TCA cycle) for the control 
of HIF PHD activity [34, 35] Fig. (2). PHDs are Fe(II)- and 2-
oxoglutarate-dependent dioxygenases known to inactivate HIF-1? 
through prolylhydroxylations followed by proteasomal degradation 
[128-131]. Oxygen being a necessary substrate of the reaction, their 
activities decrease under hypoxia [132, 133]. Assays with immobi-
lized 2-oxoglutarate and radiolabeled PHDs showed that pyruvate is 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Signaling pathway of lactate supporting HIF-1 and NF-?B activation. Lactate, its downstream effectors and influences are represented in red. 
Prolylhydroxylases (PHD) are Fe(II)- and 2-oxoglutarate-dependent oxygenases that catalyze (i) hydroxylation of hypoxia-inducible factor-1? (HIF-1?) on 2 
proline residues addressing the subunit for proteasome-mediated degradation, and (ii) inactivating hydroxylation of IKK?. Unphosphorylated I?B? represses 
nuclear factor-?B (NF-?B). Oxygen and 2-oxoglutarate (arising in the cytosol from citrate exported from mitochondria) are necessary substrates of the reac-
tions. Exogenous lactate originating e.g. from glycolytic tumor cells is taken up primarily by monocarboxylate transporter 1 (MCT1) and oxidized to pyruvate 
by lactate dehydrogenase-1 (LDH-1). The reductive arm of the reaction yields NADH + H+ from NAD+. Both pyruvate and NADH mediate lactate signaling 
intracellularly. On one hand, pyruvate functionally competes with 2-oxoglutarate leading to PHD inactivation and, consequently, HIF-1? protein stabilization 
and IKK? activation. On the other hand, NAD(P)H oxidase yields reactive oxygen species (ROS) from NADH; ROS activate a cascade leading to the phos-
phorylative inactivation of I?B? which, together with IKK? activation, account for NF-?B activation. ROS may further mediate the effects of lactate through 
either maintaining iron in an oxidized Fe3+ state and/or through oxidizing ascorbate (asc.) thereby preventing Fe3+ reduction. While in tumor cells vascular 
endothelial growth factor (VEGF) was evidenced as a final effector of lactate signaling [34], IL-8 was found to be induced by lactate in endothelial cells [36]. 
Both pathways cooperate for lactate-induced tumor angiogenesis. 
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able to displace the binding of 2-oxoglutarate on PHDs independ-
ently of hypoxia [35], offering a potential rationale for exogenous 
lactate stimulating HIF-1 activity in normoxic cancer cells. Of note, 
soft ionization mass spectrometric assays in in vitro nondenaturing 
conditions failed to detect a direct interaction between pyruvate and 
PHD2 [134]. This study using N-terminally truncated PHD2 (amino 
acids 181- 426) also failed to show PHD2 inhibition by pyruvate, 
suggesting that pyruvate may not interact directly with the 2-
oxoglutarate-binding site but would rather induce a conformational 
change interfering with the binding of 2-oxoglutarate to full length 
PHD2. This possibility remains to be demonstrated. The Verma 
study [35] and our unpublished data clearly show that pyruvate is 
more rapid and more effective than lactate in inducing HIF-1? pro-
tein stabilization, highlighting pyruvate as a potential intermediate 
supporting PHD inhibition by lactate. Pyruvate increased the tran-
scription of several HIF-1-target genes including VEGF, GLUT3, 
aldolase-A (in U87 glioma cells); and erythropoietin (EPO) in 
Hep3G human hepatoma cells [34]. The inability of NADH or cata-
lase (administered exogenously to permeabilized cells) to recapitu-
late the effects of lactate was originally interpreted to rule out an 
important contribution of redox changes to lactate-induced HIF-1 
activation in glioma cells [34]. However, the observation that 
ascorbate (a necessary PHD cofactor allowing iron reduction for 
enzyme recycling) and glutathione (GSH) block the activity of py-
ruvate later revealed that redox changes are an integral part of the 
signaling pathway [35]. This particular issue obviously warrants 
further investigation. Lactate-induced HIF-1? stabilization was 
confirmed in many cancer cell lines but surprisingly not in Hep3G 
cells where pyruvate consistently induced EPO gene transcription. 
Pyruvate also induced HIF-1? expression in normal astrocytes and 
normal human prostate epithelium [34], thus suggesting that hy-
poxia mimicry by lactate could be a physiological phenomenon.  
 Interestingly, in addition to lactate and pyruvate, Lu et al. [35] 
initially reported that oxaloacetate, ?-ketoisocaproate, ?-keto-?-
methylvalerate and ?-keto-isovalerate (possessing 2-oxo groups) 
also induced HIF-1? expression in some cancer cell lines, an activ-
ity which was not shared by citrate, fumarate, 2-oxoglutarate, suc-
cinate, acetoacetate, ?-hydroxybutyrate, pyruvaldehyde, malate and 
alanine in the same cancer cells. Their conclusion that molecular 
features mimicking those of 2-oxoglutarate are necessary for the 
biological activity has now been challenged by others having shown 
that succinate (a product of the PHD reaction), fumarate, (iso)citrate 
and 2-hydroxyglutarate (substituting the 2-oxo group by a 2-
hydroxyl group) are also potent PHD inhibitors [134-138]. Fu-
marate and succinate inhibit PHD1 to 3 but not factor inhibiting 
HIF (FIH) [137], citrate inhibits PHD3 and FIH [137], and 2-
hydroxyglutarate competitively inhibits the interaction of 2-
oxoglutarate with multiple dioxygenases including PHDs, collagen 
hydroxylases, and histone demethylases [138]. These activities link 
HIF-1 activation with the aggressive phenotype of tumors harboring 
loss of function mutations in fumarate hydratase (FH) [136, 139] or 
succinate dehydrogenases (SDHs) [135, 139]; or gain of function 
mutations in isocitrate dehydrogenase IDH1 and IDH2 supporting 
the production of 2-hydroxy-glutarate instead of 2-oxoglutarate 
from isocitrate [138, 140].  
 In macrophages, lactate was shown to increase TLR4 signaling 
and NF-?B-dependent inflammatory gene expression [141]. These 
responses were blocked using antioxidants or the MCT inhibitor 
CHC, indicating that lactate oxidation into pyruvate could play a 
role and that targeting MCT pharmacologically could inhibit lactate 
signaling. This pathway has been better characterized in human 
umbilical vein endothelial cells (HUVECs) by Végran et al. who 
demonstrated lactate-induced NF-?B activation based on a gene 
signature array showing lactate-induced IL-8 transcription [36]. 
Both ROS and PHD inhibition were shown to be equally important 
in mediating lactate signaling Fig. (2). Indeed, on one hand, lactate-
induced ROS production was evidenced to mediate the degradation 
of the NF-?B inhibitor I?B? through serine phosphorylations and 
protein degradation. On the other hand, 2-oxoglutarate dose-
dependently inhibited lactate-induced NF-?B activity and IL-8 
expression, and lactate signaling was further found to be inopera-
tive in the absence of PHD2. In support of this, Cummins et al. 
[142] have shown that hypoxia may activate NF-?B through a de-
creased hydroxylation of IKK? by PHDs, triggering the phosphory-
lation-dependent degradation of I?B?. In the study of Végran et al. 
[36], a functional link between both ROS and PHD2 pathways was 
provided by showing that targeting NAD(P)H oxidase with diphen-
ylene iodonium (inhibiting ROS production from NADH) also pre-
vented the increase in basal NF-?B activity measured after PHD2 
silencing. An important in vivo finding was that lactate-induced IL-
8 angiogenesis requires MCT4 expression in glycolytic tumor cells 
(for the release of lactate), and MCT1 expression in endothelial 
cells (for lactate uptake). Lactate shuttles in tumors, therefore, in-
fluence non-metabolic systems that could be therapeutically tar-
geted with MCT1 inhibitors. 
 Some evidence indicates that lactate could affect additional 
pathways. For example, as already mentioned before, lactic acid 
was shown to induce both transcription and protein secretion of 
TGF-?2 in primary cultures of high-grade glioma [117]. TGF-?2, in 
turn, increases the membrane expression of integrin ?v?3 and 
MMP2 expression and activation. Conversely, silencing LDH-5 
with a specific siRNA resulted in decreased TGF-?2 expression, 
MMP2 activity, and tumor cell migration in vitro. These data sug-
gest the existence of a lactate-driven autocrine signaling pathway 
coupling glycolysis with increased tumor cell migration and metas-
tasis. Others have reported lactate-induced TGF-?1 production in 
vivo [143]. Although microenvironmental acidification may cer-
tainly play a role, the molecular mechanisms regulating this path-
way are still incompletely understood. Another example of potential 
lactate signaling has been provided by immunologists: lactic acid 
(10 - 20 mM) enhances the transcription of IL-23p19 (subunit p19 
of pro-inflammatory and tumor-promoting IL-23) in monocytes 
stimulated with a TLR2/4 ligand, but low pH and sodium lactate 
were devoid of such activity [144]. In co-culture systems, lactic 
acid further enhanced IL-17A and IL-21 gene and protein expres-
sion in regulatory/memory CD4
+
 T cells [144, 145]. Although many 
evidences point at an intracellular action of lactate, the underlying 
mechanisms of this mode of signaling have not been identified to 
date. A final example of lactate signaling is the well-known regula-
tion of protein ADP-ribosylation, described in detail in the next 
section pertaining to lactate-induced angiogenesis.  
 The transcription and signaling pathways modulated by lactate 
have potentially wide spread effects on tumor metabolism, angio-
genesis and metastasis. Although some activities of lactate have 
already been elucidated, major mechanistic insights are still ex-
pected to deliver suitable therapeutic targets. In cancer, MCT1 inhi-
bition is emerging as a novel strategy with multiple action sites. It is 
now crucial to validate the contribution of MCT1 and perhaps of 
other MCTs in defined cell types with different (epi)genetic back-
grounds exposed to variable microenvironmental conditions. 
LACTATE IN TUMOR ANGIOGENESIS: CLUES FROM 
WOUND REPAIR 
 Despite wound transformation is an uncommon and rare event, 
gene expression analysis of healing skin wounds indicated a pattern 
which strongly resembles to that of highly malignant cancers [146]. 
Striking similarities between wounds and tumors have been pointed 
out by Harold Dvorak [147] who, in the mid 1980s, provocatively 
compared tumors to wounds that do not heal. Coherently with these 
observations, wounds, similar to tumors, are notoriously hypoxic 
lesions characterized by an increased glycolytic rate and lactate 
secretion [148, 149]. In normal physiological conditions, on aver-
age, lactate levels range from 1.8 mM to 2.0 mM, whereas in 
wounds and tumors it may reach 6 - 15 mM. [10, 16, 24, 37, 150]. 
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Several efforts have been made in order to understand whether 
lactate accumulation in wounds was just an epiphenomenon or ac-
tually involved in the wound repair process. It is currently recog-
nized that lactate concentrations similar to those present in wounds 
improve by themselves many processes essential to the regenerative 
process. In the next paragraphs, we review the main evidences 
pointing at a functional link between lactate production and angio-
genesis in the context of wound healing, which would logically also 
exerts an influence in cancer despite few specific data are available 
today. 
 Wound healing is one of the most composite biological fea-
tures, involving several signaling cascades and biological processes 
that have to be transiently activated and coordinated in order to lead 
to proper wound repair [151]. Among these processes, the onset of 
angiogenesis supporting the development of new blood vessels 
from pre-existing ones is a critical event to restore perfusion, oxy-
genation, and nutrient supply. Lactate has been shown to exert sev-
eral pro-angiogenic activities: it stimulates VEGF secretion by 
macrophages [152], endothelial cell migration [38], vascular 
morphogenesis [153] and the recruitment of circulating vascular 
progenitor cells [154]. In addition, lactate has been shown to trigger 
tissue repair by augmenting collagen deposition, TGF-? production, 
and fibroblast proliferation [37, 39, 155]. Several lactate-sensitive 
pathways support these biological responses. In order to understand 
the underlying mechanisms, it is important to point out that lactate-
induced angiogenesis rely on lactate oxidation by LDH-1 [153, 
154], calling into play the products of the enzymatic reaction 
(namely pyruvate and NADH) and lactate transporters. On one 
hand, raising levels of pyruvate interfere with PHD activity to acti-
vate HIF-1 and NF-?B, as mechanistically detailed above and in 
Fig. (2). HIF-1 is a master regulator of angiogenesis: its activation 
is sufficient to trigger the expression of several growth factors re-
quired for angiogenesis, among which VEGF, basic fibroblast 
growth factor (bFGF) and stromal cell-derived factor-1 (SDF-1) 
[156, 157]. While VEGF and bFGF regulate angiogenesis through 
binding with their cognate receptors on endothelial cells, the com-
bined action of VEGF and SDF-1 in response to lactate is involved 
in the recruitment of endothelial progenitor cells for vasculogenesis 
at the wounded site. Milovanova et al. [154] indeed showed that 
lactate is sufficient to trigger the recruitment and in vivo vascular 
differentiation of CD34+ cells in Matrigel plugs, and both phe-
nomenons were blocked using neutralizing antibodies against 
VEGF and SDF-1. They were also blocked with LDH inhibitors 
(oxamate and siRNAs), the NAD(P)H oxidase inhibitor apocinyn, 
the antioxidants N-acetylcysteine and dithioerythritol, and a specific 
siRNA against HIF-1, thus confirming lactate-induced HIF-1 acti-
vation as an important pathway for vasculogenesis. On the other 
hand, NADH production associated with lactate oxidation depletes 
the pool of NAD
+
, which has consequences on NAD
+
-dependent 
enzymes such as GAPDH (explaining in part why lactate-fueled 
respiration inhibits glycolysis [4, 124]) and PARPs. PARPs use 
NAD
+
 for the synthesis of polyadenosine diphosphoribose 
(pADPR) used for the posttranslational modification of histones 
and other proteins including p53, Sp-1, and NF-?B [158, 159]. By 
depleting NAD
+
, LDH-1 activity logically reduces pADPR synthe-
sis and affects gene transcription [152, 160]. In the context of 
wound healing, Ghani et al. [150] reviewed the work of Thomas 
Hunt having shown that VEGF transcription and synthesis and col-
lagen transcription are enhanced by the lactate-mediated downregu-
lation of pADPR, which thereby participates in lactate-induced 
angiogenesis. There is further evidence that lactate can decrease the 
mono-ADP-ribosylation of VEGF (leading to its activation in 
macrophages and in endothelial cells) [152, 161, 162] and of colla-
gen PHD, which increases its enzymatic activity and collagen matu-
ration in fibroblasts [163]. 
 To date, whether lactate exerts similar influences in cancer as 
those evidenced in wounds is largely unknown. To our knowledge, 
there is no report addressing the influence of lactate on ADP-
ribosylation in tumors. Recently, Lu et al. demonstrated increased 
VEGF production in several cancer cell lines exposed to lactate 
[34], but these findings were never translated in functional assays. 
Perhaps the most extensive study is that of Végran et al. [36], link-
ing lactate-induced NF-?B activation in endothelial cells with IL-8-
mediated autocrine angiogenesis. The authors documented that this 
pathway drives endothelial cell migration and tube formation in 
vitro, and lactate-induced tumor angiogenesis in vivo. The latter 
experiment involved the co-injection of notably Warburg WiDr 
tumor cells with HUVECs in Matrigel plugs in immunodeficient 
mice, wherein either the use of MCT4-deficient tumor cells (unable 
to release lactate), the use of MCT1-deficient HUVECs (unable to 
take-up lactate), or an IL-8-blocking antibody all repressed tumor 
angiogenesis and delayed tumor growth [36]. These experiments 
further confirmed MCT1 as an antitumor target. While MCT1 inhi-
bition in oxidative tumor cells exerts antimetabolic activities [4], 
targeting MCT1 in endothelial cells could exert potent anti-
angiogenic effects [36]. Further studies are now needed to define 
the therapeutic dimension of the strategy. 
CONCLUDING REMARKS 
 Although the involvement of lactate in wound healing and the 
existence of lactate shuttles in normal tissue physiology have been 
identified years if not decades ago, lactate in cancer has attracted 
attention only recently. Most of its tumor-growth activities still 
need to be discovered. In tumors, lactic acid is exported from glyco-
lytic tumor cells (being aerobic or anaerobic) and stromal cells. 
However, theoretically, glycolysis uncoupled from any other meta-
bolic pathway would yield lactate but no proton. Lactic acidosis 
therefore involves metabolic activities different from glycolysis 
itself and relies on the necessity of a pH gradient across the plasma 
membrane to export lactate through MCTs. There are two potential 
readings: (i) although many other proton transporters are overex-
pressed in glycolytic cancer cells, lactate serves to export protons to 
prevent intracellular acidosis; and/or (ii) protons serve to export 
lactate in order to maintain the pH buffering capacity of the LDH-5 
reaction. Far to be trivial, resolving this black box could help to 
position MCT inhibitors with respect to inhibitors of other proton 
transporters, such as CAIX, NHE-1 and membrane-bound V-
ATPase, most of which are currently undergoing clinical trials [9]. 
 Once exported, lactate and protons may separately exert tumor-
promoting influences, or act in a coordinated manner. Coordinated 
activities have been described in the context of the lactic acid in-
duction of IL-23 in monocytes, an activity that cannot be repro-
duced with low pH or sodium lactate when administered separately 
[144]. If, as exemplified in many studies and proposed in others, the 
intracellular activities of lactate first require MCT1-mediated lac-
tate uptake, protons are necessarily involved. Intracellular activities 
include the use of lactate as an oxidative fuel, lactate signaling sup-
porting angiogenesis (HIF-1 and NF-?B activation) [34-36] and 
metastasis (induction of TGF?, HA and CD44) [113, 114, 117], and 
the lactate regulation of mono/poly-ADP-ribosylation in angiogene-
sis [150]. A consequence of this is that targeting MCT1 with a sin-
gle therapeutic agent could exert multiple anticancer influences. A 
first MCT1 inhibitor, AZD3965, is currently entering Phase I/II 
clinical trials for advanced solid tumors 
(http://science.cancerresearchuk.org/). Its evaluation could help to 
better define the role of MCT1 in cancer. Lactate may also exert 
MCT-independent activities in tumors, as done by protons. Over the 
past decades, the contribution of low pHe to tumor progression and 
metastasis has been well characterized but the direct activities of 
lactate are still to be explored. Some could be conveyed by GPR81, 
a G protein-coupled receptor initially identified in adipocytes and 
recently revealed as a receptor for lactate [164, 165]. 
 In summary, while many of the biological activities of lactic 
acid in tumors could be targeted therapeutically with MCT inhibi-
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tors and other strategies have been identified to exploit tumor acid-
ity independently of lactate, most intrinsic activities of the lactate 
anion remain to be identified, characterized and, potentially, tai-
lored for therapy. 
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